Peter D. Feldman

3.7k total citations
41 papers, 2.7k citations indexed

About

Peter D. Feldman is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pharmacology. According to data from OpenAlex, Peter D. Feldman has authored 41 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Psychiatry and Mental health, 10 papers in Clinical Psychology and 6 papers in Pharmacology. Recurrent topics in Peter D. Feldman's work include Schizophrenia research and treatment (21 papers), Attention Deficit Hyperactivity Disorder (12 papers) and Bipolar Disorder and Treatment (11 papers). Peter D. Feldman is often cited by papers focused on Schizophrenia research and treatment (21 papers), Attention Deficit Hyperactivity Disorder (12 papers) and Bipolar Disorder and Treatment (11 papers). Peter D. Feldman collaborates with scholars based in United States, Singapore and Hungary. Peter D. Feldman's co-authors include Alan Breier, Mauricio Tohen, T. Jacobs, Gary D. Tollefson, Richard C. Risser, Haitao Gao, Joseph R. Calabrese, Charles L. Bowden, Carlos A. Zarate and Trisha Suppes and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Brain Research.

In The Last Decade

Peter D. Feldman

40 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter D. Feldman United States	27	2.1k	526	459	334	319	41	2.7k
Martina Hummer Austria	31	2.9k 1.4×	461 0.9×	681 1.5×	296 0.9×	247 0.8×	69	3.7k
Donna A. Wirshing United States	28	2.4k 1.1×	379 0.7×	653 1.4×	266 0.8×	213 0.7×	50	3.4k
Martin Brecher United States	28	3.3k 1.6×	903 1.7×	489 1.1×	249 0.7×	202 0.6×	74	3.9k
William M. Glazer United States	29	2.1k 1.0×	301 0.6×	644 1.4×	225 0.7×	577 1.8×	103	3.0k
Raymond Sanchez United States	31	2.6k 1.2×	1.0k 2.0×	498 1.1×	196 0.6×	231 0.7×	68	3.3k
William C. Wirshing United States	31	2.8k 1.3×	426 0.8×	824 1.8×	458 1.4×	297 0.9×	90	3.9k
S.H. Hamilton United States	18	2.4k 1.1×	725 1.4×	483 1.1×	131 0.4×	149 0.5×	41	3.0k
James M. Martinez United States	20	1.4k 0.7×	473 0.9×	260 0.6×	233 0.7×	254 0.8×	47	2.5k
Georges M. Gharabawi United States	27	1.5k 0.7×	455 0.9×	399 0.9×	177 0.5×	166 0.5×	50	2.1k
Caroline Corves Germany	6	1.7k 0.8×	311 0.6×	360 0.8×	265 0.8×	130 0.4×	11	2.2k

Countries citing papers authored by Peter D. Feldman

Since Specialization

Citations

This map shows the geographic impact of Peter D. Feldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter D. Feldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter D. Feldman more than expected).

Fields of papers citing papers by Peter D. Feldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter D. Feldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter D. Feldman. The network helps show where Peter D. Feldman may publish in the future.

Co-authorship network of co-authors of Peter D. Feldman

This figure shows the co-authorship network connecting the top 25 collaborators of Peter D. Feldman. A scholar is included among the top collaborators of Peter D. Feldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter D. Feldman. Peter D. Feldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanaka, Yoko, Luís Augusto Rohde, Ling Jin, Peter D. Feldman, & Himanshu P. Upadhyaya. (2013). A Meta-analysis of the Consistency of Atomoxetine Treatment Effects in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder from 15 Clinical Trials Across Four Geographic Regions. Journal of Child and Adolescent Psychopharmacology. 23(4). 262–270. 16 indexed citations

Ascher‐Svanum, Haya, et al.. (2012). Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. International Journal of General Medicine. 5. 391–391. 10 indexed citations

Stauffer, Virginia L., Bruce J. Kinon, Haya Ascher‐Svanum, et al.. (2011). Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophrenia Research. 134(2-3). 195–201. 34 indexed citations

Liu‐Seifert, Hong, Olawale Osuntokun, & Peter D. Feldman. (2011). Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Comprehensive Psychiatry. 53(1). 107–115. 32 indexed citations

Mohs, Richard C., et al.. (2009). Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study. American Journal of Geriatric Psychiatry. 17(9). 752–759. 43 indexed citations

Spencer, Thomas, Christopher J. Kratochvil, R. Bart Sangal, et al.. (2007). Effects of Atomoxetine on Growth in Children with Attention-Deficit/Hyperactivity Disorder Following up to Five Years of Treatment. Journal of Child and Adolescent Psychopharmacology. 17(5). 689–699. 50 indexed citations

Quintana, Humberto, Mark E. Bangs, Janet L. Ramsey, et al.. (2007). Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder—A preliminary tolerability and efficacy study. Clinical Therapeutics. 29(6). 1168–1177. 28 indexed citations

Trzepacz, Paula T., David W. Williams, Peter D. Feldman, et al.. (2007). CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. European Neuropsychopharmacology. 18(2). 79–86. 54 indexed citations

Chou, Kelvin L., Susan Messing, David Oakes, et al.. (2005). Drug-Induced Psychosis in Parkinson Disease. Clinical Neuropharmacology. 28(5). 215–219. 62 indexed citations

10.

Deyn, Peter Paul De, Manuel Martín Carrasco, Walter Deberdt, et al.. (2004). Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry. 19(2). 115–126. 142 indexed citations

11.

Tohen, Mauricio, K. N. Roy Chengappa, Trisha Suppes, et al.. (2004). Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. The British Journal of Psychiatry. 184(4). 337–345. 214 indexed citations

12.

Bitter, István, Martín Dossenbach, S. Brook, et al.. (2003). Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 28(1). 173–180. 98 indexed citations

13.

Feldman, Peter D., Christopher Kaiser, John Kennedy, et al.. (2003). Comparison of Risperidone and Olanzapine in the Control of Negative Symptoms of Chronic Schizophrenia and Related Psychotic Disorders in Patients Aged 50 to 65 Years. The Journal of Clinical Psychiatry. 64(9). 998–1004. 26 indexed citations

14.

Breier, Alan, et al.. (2002). Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biological Psychiatry. 52(5). 438–445. 149 indexed citations

15.

Tohen, Mauricio, K. N. Roy Chengappa, Trisha Suppes, et al.. (2002). Efficacy of Olanzapine in Combination With Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy. Archives of General Psychiatry. 59(1). 62–62. 290 indexed citations

16.

Sanger, T.M., Mauricio Tohen, Eduard Vieta, et al.. (2002). Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. Journal of Affective Disorders. 73(1-2). 155–161. 50 indexed citations

17.

Zhang, Fan, P E Keck, Peter D. Feldman, et al.. (2001). Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. Journal of Affective Disorders. 67(1-3). 133–140. 21 indexed citations

18.

Street, J., et al.. (2001). Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. International Journal of Geriatric Psychiatry. 16(S1). S62–S70. 67 indexed citations

19.

Clark, W. Scott, J. Street, Peter D. Feldman, & Alan Breier. (2001). The Effects of Olanzapine in Reducing the Emergence of Psychosis Among Nursing Home Patients With Alzheimer's Disease. The Journal of Clinical Psychiatry. 62(1). 34–40. 77 indexed citations

20.

Feldman, Peter D. & Hylan C. Moises. (1987). Adrenergic responses of baroreceptive cells in the nucleus tractus solitarii of the rat: a microiontophoretic study. Brain Research. 420(2). 351–361. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact